Figure 3From: Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors Effect of TLR agonists on tumor-specific CTL. CT26 tumors were implanted into BALB/c mice as described in Figure 1. Spleen cells and tumor infiltrating lymphocytes were isolated one day after the second treatment, stimulated ex vivo with AH-1 peptide, and monitored for IFNγ secretion by ELIspot assay. Results represent the mean + SD of 6 mice from 2 independent experiments. *, p < 0.05; **, p <0.01.Back to article page